活性γCu380IUD与TCu380IUD及吉妮330IUD临床效果观察

目的观察比较活性γCu380IUD、TCu380IUD及吉妮330IUD临床避孕效果。方法2003年11月～2005年12月本院选择自愿放置IUD的已婚育龄妇女300例,随机分成三组(各100例),分别放置活性γCu380IUD、TCu380IUD及吉妮330IUD,并于放置后1、3、6、12、24个月进行随访。结果三种IUD放置24个月后比较其脱落率、带器妊娠率、因症取出率及累积续用率均无统计学差异(p>0.05)。结论三种IUD均具有脱落低、带器妊娠率低、因症取出率低及累积续用率较高的优点,其避孕效果良好,可在临床上推广使用。     

人工流产术后即时放置GyneFix IUD、MCu IUD和TCu220 IUD避孕效果分析

目的:评价新型宫内节育器(IUD)GyneFix IUD和MCu IUD及传统节育器TCu220IUD的避孕效果。方法:以人工流产术后志愿放置IUD的690例为对象,随机分为3组,分别于人工流产术后即时放置Gyne Fix IUD、MCu IUD和TCu220IUD。结果:GyneFix IUD,MCu IUD和TCu220IUD使用12个月带器妊娠率分别为0.48%、0.85%、3.75%,脱落率分别为0.93%、0.85%、2.92%,因症取出率分别为2.80%、3.81%、6.25%,续用率分别为95.80%,94.49%,87.08%,放置IUD后月经异常发生率分别为8.88%、5.93%、12.5%。结论:GyneFix IUD、MCu IUD和TCu220IUD避孕效果均较理想,但TCu220IUD可能是放置型号不易掌握,带器妊娠、脱落、月经异常发生率较两种新型IUD高。     

373例哺乳期放置TCu380A 1年临床效果观察

目的:观察哺乳期放置TCu380A宫内节育器(IUD)的临床效果。方法:选择2006年6月2日～2007年6月3日期间到安阳市汤阴县宜沟镇计划生育服务站要求放置IUD观察对象373例。采用生存分析法,分析观察对象使用IUD的1年期带器妊娠率、脱落率、因症取出率等。结果:随访12个月末1例观察对象失访,无带器妊娠者,脱落相关终止率为0.27/每百妇女/年,因症取出率为1.07/每百妇女/年,与IUD使用相关终止率为1.34/每百妇女/年。结论:哺乳期放置Tcu380A宫内节育器安全、有效,优于其他放置时期。     

放置MYCuIUD与MCuⅡIUD12个月效果观察

目的:观察MYCu宫内节育器(MYCuIUD)与MCuⅡ功能性宫内节育器(MCuⅡIUD)的临床效果及安全性。方法:多中心随机放置MYCuIUD(MYCu组)、MCuⅡIUD(MCuⅡ组)各700例,术后第1、3、6、12个月随访。结果:放置满12个月,MYCu组与MCuⅡ组累积带器妊娠率分别为0.43/百妇女年、0.73/百妇女年;累积脱落率分别为0.43/百妇女年、0.44/百妇女年;因医疗原因取出分别为1.30/百妇女年、1.88/百妇女年;主要副作用为出血和疼痛;以上差异均无统计学意义(P>0.05)。放置后1、3个月时月经异常及腰腹疼痛发生率MCuⅡ组高于MYCu组(P<0.05)。结论:MYCuIUD与MCuⅡIUD同样具有抗生育效果好、脱落率低、副作用发生率低的特点,放置MYCuIUD可减少IUD放置初期的出血和疼痛。     

放置元宫型Cu365与TCu220C宫内节育器12个月临床效果观察

<正>宫内节育器(IUD)为我国育龄妇女的主要避孕措施,目前约70%妇女选用IUD作为避孕方法,占世界使用IUD避孕人数的80%[1]。国内外推广带铜IUD,增强了避孕效果,但置器者因铜离子对子宫     

放置MCu IUD24个月的临床效果观察

目的:观察新型宫内节育器MCuIUD的临床效果。方法:将600例置器妇女随机分为2组,分别放置MCu、MLCu两种IUD各300例,随访观察24个月,对其避孕效果、副反应、续用率进行观察比较与评价。结果:24个月累积续用率MCuIUD为93.29%,MLCuIUD为84.05%,比较差异有显著性意义(P<0.05);MCuIUD、MLCuIUD脱落率分别为1.00%、7.44%,差异有极显著性意义(P<0.01);因症取出率分别为2.36%、6.48%,差异有显著性意义(P<0.05);带器妊娠率分别为2.68%,1.35%,差异无显著性意义(P>0.05)。结论:MCuIUD是一种续用率高、脱落率低、因症取出率低、妊娠率较低、可接受性好的宫内节育器,值得临床推广。     

带器失败妇女放置吉妮IN IUD380例效果观察

宫内节育器(IUD)是我国目前应用最为广泛的避孕工具，具有安全、有效、经济、简便及可逆等优点，育龄群众乐于接受。但是由于个体的差异和IUD的原因，导致部分妇女带器失败，非意愿停止使用。为了选择一种避孕效果好、副反应低的IUD，我市于2002年4月引进新型宫内节育器吉妮IN IUD并应用于临床，经对380例既往使用普通IUD失败的妇女放置吉妮IN IUD1年的定期随访观察，使用效果满意，现报告如下。     

吉妮IN、爱母IUD及元宫铜300型IUD临床避孕效果观察

目的 观察吉妮IN IUD、爱母IUD、元宫铜300型IUD的临床避孕效果。方法 2004年1月-2007年1月本站采用对比研究,以随机方法放置3种IUD 1380例,其中吉妮IN 428例,爱母IUD 472例,元宫型IUD 480例,于放置后1、3、6、12个月进行随访。结果 吉妮IN IUD,爱母IUD和元宫铜300型IUD使用12个月带器妊娠率分别为0.48%、0.85%、3.75%,脱落率分别为0.93%、0.85%、2.92%,因症取出率分别为2.80%、3.81%、6.25%,续用率分别为95.80%、94.49%、87.08%,放置IUD后月经异常发生率分别为8.88%、5.93%、12.5%。结论 吉妮INIUD、爱母IUD和元宫铜300型IUD避孕效果均较理想,前两种新型IUD具有脱落率低、因症取出率低、累积续用率高的优点,值得临床推广应用。根据对象的自身条件,选择合适的IUD,可提高避孕效果,减少副作用的发生。     

TCu220C与TCu380A IUD体外细胞毒性研究

目的:评价两种含铜宫内节育器体外细胞毒性。方法:采用TCu220C和TCu380A,10%FBS-DMEM浸提后,与L929细胞接触培养,通过倒置相差显微镜观察其形态,采取MTT(四唑盐)比色法量化细胞毒性,计算相对增值率(RGR),并进行毒性评价。结果:TCu220C表现出轻度的细胞毒性(1～2级),TCu380A表现出明显的细胞毒性(4级)。结论:相同形状的两种含铜宫内节育器因含铜面积不同,其表现出来的细胞毒性也不同,含铜面积越大,细胞毒性越大。     

Tcu380A、Tcu220宫内节育器放置5年避孕效果观察

目的 探讨Tcu380A、Tcu220宫内节育器放置5年的避孕效果.方法 对放置Tcu380A、Tcu220宫内节育器的各200例妇女进行随访,观察3个月内不良反应和5年避孕效果.结果 与TCu220 IUD 比较,TCu380A IUD在带器妊娠、下移、与IUD相关原因终止取出等方面发生率低,续用率高,两者差异有统计学意义 （P〈005）,3个月内不良反应两者比较差异无统计学意义（P〉005）.结论 Tcu380A 5年避孕效果比Tcu220避孕效果好,是比较理想的宫内节育器.     

Levonorgestrel-releasing and copper intrauterine devices and the risk of breast cancer

Background

This study compares the risk of breast cancer for levonorgestrel-releasing intrauterine devices (LNG_IUD) versus copper IUDs (CU_IUD) in women younger than 50 years of age.

Study Design

Retrospective, population-based, case-control study using cancer registers in Finland and Germany, powered to exclude a 1.5-fold risk of breast cancer.

Results

Analysis of 5113 breast cancer cases diagnosed 2000–2007 and 20,452 controls — matched by year of birth and area of residence — yielded relative risk estimates approaching unity with 95% CI crossing 1.0 for all comparisons, including ever-use of LNG_IUD versus CU_IUD (adjusted OR, 0.99; 95% CI, 0.88–1.12) and current use at time of diagnosis (adjusted OR, 0.85; 95% CI, 0.52–1.39), as well as for sub-analyses by country, age, tumor characteristics and period, recency and duration of use prior to diagnosis.

Conclusion

This study does not indicate an increased risk of breast cancer for users of LNG_IUD. No indications for tumor promotion or tumor induction were found.     

吉妮与爱母宫内节育器使用24个月的临床效果观察

目的:比较吉妮与爱母两种宫内节育器(IUD)的临床使用效果。方法:对自愿要求放置IUD避孕而无禁忌证的育龄妇女236例,随机分成两组,分别放置吉妮IUD(117例)和爱母IUD(119例)。结果:两种IUD2年累积带器妊娠率分别为每百妇女年0.86和2.84,差异无统计学意义(P>0.05);2年累积脱落率分别为每百妇女年0.85和9.57,差异有统计学意义(P<0.05);2年累积因症取出率分别为每百妇女年0.00和5.31,差异有统计学意义(P<0.05);2年累积续用率分别为每百妇女年98.29和83.19,差异有统计学意义(P<0.05)。结论:吉妮与爱母两种IUD均具有较好的临床效果,其中吉妮IUD具有较好的有效性和可接受性。     

花式IUD与GT300型含铜宫形IUD应用效果对比观察

目的:观察放置花式宫内节育器(HCu280IUD)与GT300型含铜宫形(GT300)IUD的临床使用效果。方法:分别放置HCu280和GT300IUD各500例,于放置后6,12和24个月进行随访,比较两种IUD的脱落率、带器妊娠率、续用率及各种副反应发生率。结果:HCu280与GT300IUD续用率均大于80%,带器妊娠率、因症取出率、脱落率和续用率差异均无统计学意义(P>0.05);HCu280组大部分副反应发生率低于GT300型组(P<0.01)。结论:HCu280和GT300型IUD均安全有效,HCu280IUD的副反应更少一些。     

A randomized trial on the clinical performance of Nova T380 and Gyne T380 Slimline copper IUDs

PURPOSE: The objective of this open randomized study was to compare the clinical performance of Nova T380 and Gyne T380 Slimline copper intrauterine devices (IUDs). MATERIALS AND METHODS: Eligible for analyses were 957 Norwegian parous women aged 18-45 years. Clinical performance was measured upon the removal of IUD due to contraceptive failure, expulsion, bleeding, pain, pelvic inflammatory disease and other medical reasons during a 5-year study period. RESULTS: The discontinuation rate due to contraceptive failure was significantly higher in the first year for Nova T380 users than for Gyne T380 Slimline users, whereas no differences were observed thereafter (the 5-year cumulative failure rates were 4.4% and 2.2%, respectively, per 100 women). However, the partial expulsion rate was significantly higher in the first year for Gyne T380 Slimline users than for Nova T380 users (the 5-year cumulative rates were 3.4% and 1.1,% respectively, per 100 women). No other major differences in reasons for discontinuation were found between the study groups. There was a slight nonsignificant increase in hemoglobin levels for both study groups over the course of the study. CONCLUSION: Clinical performance was considered satisfactorily high for both devices.     

月经间期放置MYCu宫内节育器临床效果的比较性研究

目的:了解第三代爱母宫内节育器(MYCu IUD)在月经间期放置的临床效果、副作用及对生活质量的影响。方法:对要求放置IUD避孕的育龄妇女,在月经间期随机放置MYCu IUD(MYCu组,368例)与TCu 380AIUD(TCu380A组,369例),放置后1、3、6、12个月随访观察,记录使用情况。结果:置器后12个月MYCu组与TCu 380A组随访率分别为99.45%、100.00%;置器12个月累积续用率分别为每百妇女年94.02、91.87(P0.05);带器妊娠率分别为每百妇女年0.56、0.00(P=0.1703);脱落率分别为每百妇女年0.57、1.95(P=0.0947);无因IUD下移而停用者;因症终止率分别为每百妇女年3.01、6.03(P=0.0849)。置器后1、3、6个月副作用发生率MYCu组明显低于TCu380A组(P0.05)。两组对象相关生活质量均得到改善。结论:放置MYCu IUD较TCu 380AIUD疼痛和出血的副作用少,续用率、避孕效果与TCu 380AIUD相当,是一种临床效果好、副作用发生率较低的新型IUD。     

去尾丝HCu280型花式IUD临床效果观察

目的:探讨放置去尾丝HCu280型花式宫内节育器(IUD)的临床效果,为推广使用提供科学依据。方法:21~45岁已婚已育且无放置IUD禁忌证妇女中,选择自愿放置去尾丝HCu280型花式IUD妇女200例为观察对象(HCu280IUD组),以选择放置TCu380AIUD妇女198例为对照(TCu380AIUD组),分别于放置后1、3、6和12个月进行随访,比较两组避孕效果、副作用主诉情况。结果:置器12个月HCu280IUD组和TCu380AIUD组带器妊娠率分别为每百妇女年0和0.5(P0.05);脱落率分别为每百妇年0.5和4.2(P0.05);与IUD使用相关终止率分别为每百妇女年3.5和9.6(P0.05);总终止率分别为每百妇女年4.0和10.1(P0.05);续用率分别为每百妇女年96.0和89.9。置器后1、3、6、12个月副作用主诉率,HCu280IUD组低于TCu380AIUD组。结论:HCu280型花式IUD避孕效果好,副作用主诉少,续用率高。     

Use of the Mirena™ LNG-IUS and Paragard™ CuT380A intrauterine devices in nulliparous women: Release date 15 December 2009 SFP Guideline 20092

Two intrauterine devices (IUDs) are available in the United States, the levonorgestrel-bearing intrauterine system (Mirena™) and the copper-bearing T380A (Paragard™). These devices have very low typical-use failure rates but are used by only a minority of women. In particular, there is concern about their use in nulliparous women. We review the available data to address common concerns about using IUDs in this population and show that nulliparous women desiring effective contraception should be considered candidates for IUDs.     

A comparison of the clinical performance, contraceptive efficacy, reversibility and acceptability of Norplant implants and Ortho Gynae T380 intrauterine copper contraceptive device

In this comparative study, the five-year continuity rate of 53.7% in the Norplant implants group was comparable to that of 52.7% in the copper IUD group. The difference was not statistically significant. Only one accidental pregnancy occurred during the five years of copper IUD use.Desire for future pregnancy was the main reason for removal in the Norplant implants group (35.9%) while expulsion of the IUD (13.2%) was the main reason for removal of the copper IUD. Menstrual disturbance was not a major side-effect in either group.The post-removal conception rates of 78.6% in the Norplant implants group and 75.0% in the copper IUD were good and comparable.Both the Norplant implants and copper IUD are acceptable and effective contraceptive methods in Singapore.     

A comparative study of the levonorgestrel-releasing intrauterine system Mirena versus the Copper T380A intrauterine device during lactation: breast-feeding performance, infant growth and infant development

BACKGROUND: Mirena is a levonorgestrel-releasing intrauterine system (LNG-IUS) that provides highly effective and long-acting progestogen-only contraception. OBJECTIVE: The objective of this study was to analyze the possible effects of using LNG-20 microg IUS on breast-feeding performance, infant growth and infant development during the first postpartum year as compared with the Copper T380A intrauterine device (Cu T380A IUD). DESIGN: This study is a prospective, controlled and randomized trial. SETTING: The study was conducted at the Department of Obstetrics and Gynecology, Assiut University Hospital, Egypt. METHODS: Three hundred twenty lactating women asking for initiation of contraception during the early postpartum stage were assigned randomly into two groups, the LNG-20 microg IUS group (n=163) and the Cu T380A group (n=157). The insertions were done 6-8 weeks postpartum. Each participant was followed up at three monthly intervals after insertion and until the first birthday of her baby. During these visits, the breast-feeding pattern was assessed, certain infant physical growth parameters were measured and a set of infant development tests was performed. RESULTS: No pregnancy occurred in both groups. There were no significant differences in the net continuation rates between the two groups (89.3 for LNG-IUS vs. 90.9 for Cu T380A). The LNG-20 microg IUS group had comparable rates of breast-feeding continuation, complete weaning, full breast-feeding and partial breast-feeding, with the Cu-IUD group. No statistically significant differences were found between groups with regard to all infant physical growth parameters and various infant development tests. CONCLUSION: The findings of the current study confirm that the use of LNG-20 microg IUS during the first postpartum year in lactating women provides highly effective and acceptable contraception and does not negatively influence breast-feeding or the growth and development of breast-fed infants.